CAMBRIDGE, Mass. - Foghorn Therapeutics Inc. (NASDAQ:FHTX), a biotech firm engaged in developing a new class of gene expression-targeted medicines, announced today the appointment of Kristian Humer as its Chief Financial Officer. Humer, with a broad financial and life sciences background, assumes his role immediately, bringing over two decades of financial industry experience to the company.
Humer's appointment comes as Foghorn prepares for significant milestones in 2024, including clinical data for its lead program FHD-286 in acute myeloid leukemia, and an Investigational New Drug (IND) filing for FHD-909 in collaboration with Lilly. President and CEO Adrian Gottschalk expressed confidence in Humer's ability to steer the company's financial strategy during this pivotal time.
Humer's extensive experience includes a 14-year stint in the life science sector, complemented by 20 years on Wall Street. His previous role at Viridian Therapeutics as CFO and Chief Business Officer saw him leading financial strategy and business development initiatives. Humer's career also includes key positions at Citi, Lehman Brothers, UBS, and Merrill Lynch.
Foghorn Therapeutics is at the forefront of drug discovery in chromatin biology, a novel and significant area of research with the potential to address unmet medical needs, particularly in challenging cancer treatments. The company's Gene Traffic Control® platform is central to its approach, enabling systematic study and validation of drug targets within the chromatin regulatory system.
While Humer's appointment is a strategic move for Foghorn, it is important to note that the biotechnology sector is subject to uncertainties and risks. The company's forward-looking statements regarding expected clinical trial data and regulatory filings are based on current expectations and are inherently uncertain.
The information for this article is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.